Noah Editorial
Blog
Timely research perspectives, biotech market signals, and clinical updates in a cleaner long-form reading format.
October 9, 2026
•Research ProgressBCMA Target Intelligence 2026: Approved Therapies, Late-Stage Pipeline and Competitive Questions
A 2026 BCMA target intelligence brief covering approved therapies, late-stage challengers, treatment-line differences, clinical evidence, safety, sequencing, and competitive questions in multiple myeloma.
By Linda
October 9, 2026
•ComparisonBest AI Tools for Clinical Guideline Recommendation Comparison (2026)
Compare the best AI tools for clinical guideline recommendation comparison in 2026, with a real AF anticoagulation case using ACC/AHA/ACCP/HRS, ESC, and NICE.
By Linda
October 9, 2026
•ComparisonBest AI Tools for Drug Resistance Mechanism Analysis (2026)
Compare AI tools for drug resistance mechanism analysis in 2026. Learn how AI maps on-target escape, bypass signaling, and non-genetic resistance using an osimertinib NSCLC case.
By Linda
October 9, 2026
•ComparisonBest AI Tools for Drug Target Validation Assessment (2026)
Compare AI tools for drug target validation in 2026. Learn how AI can assess genetic, biological, causal, target-engagement, and clinical evidence using a TREM2 Alzheimer's disease case.
By Linda
October 9, 2026
•ComparisonBest AI Tools for Regulatory Decision Evidence Review (2026)
Compare AI tools for regulatory evidence review using Qalsody, covering FDA and EU approval pathways, evidence gaps, and post-approval obligations.
By Linda
October 9, 2026
•Research ProgressCD47 Competitive Landscape 2026: Clinical Programs, Safety Signals and Development Strategy
A 2026 CD47 competitive landscape covering clinical programs, safety liabilities, failure analysis, modality differentiation, biomarker strategy, and development implications.
By Linda
October 9, 2026
•Research ProgressCLDN18.2 Drug Pipeline 2026: How to Track Assets, Biomarkers and Development Milestones with AI
A practical 2026 CLDN18.2 pipeline-intelligence tutorial covering asset mapping, biomarker strategies, development stages, zolbetuximab milestones, and modality comparison.
By Linda
October 9, 2026
•Research ProgressEGFR Osimertinib Resistance in NSCLC 2026: Mechanisms, Biomarkers and Combination Strategies
A 2026 translational review of osimertinib resistance in EGFR-mutant NSCLC, covering mechanisms, biomarkers, patient stratification, and next-line strategies.
By Linda
October 9, 2026
•How-toHow to Extract Evidence from Medical Research Papers with AI: Step-by-Step Guide
Learn how to extract structured, source-traceable evidence from medical research papers with AI, including PICO, endpoints, results, safety data, provenance, and QA.
By Linda
October 9, 2026
•Research ProgressHow to Investigate FcRn and Its Competitive Pipeline with AI
A 2026 FcRn target intelligence brief covering approved therapies, Phase III challengers, dosing, durability, safety, and competitive questions in generalized myasthenia gravis.
By Linda
October 9, 2026
•How-toHow to Find Research Gaps from Biomedical Literature with AI: Step-by-Step Guide
Learn how to find and validate real research gaps in biomedical literature with AI, using ctDNA-guided adjuvant treatment in stage II colon cancer as a worked example.
By Linda
October 9, 2026
•How-toHow to Research a Drug Pipeline with AI: From Target Search to Development Milestones
Learn how to research a drug pipeline with AI using a representative EGFR landscape, from asset mapping and milestones to current development status.
By Linda